| 0.6102 -0.069 (-10.13%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.51 | 1-year : | 2.02 |
| Resists | First : | 1.29 | Second : | 1.73 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.6 | Second : | 0.5 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.81 |
| MA(100) : | 1.4 |
MA(250) : | 3.44 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.3 |
D(3) : | 30 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 8.3 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACTU ] has closed above bottom band by 9.5%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.69 | 0.69 - 0.69 |
| Low: | 0.6 - 0.6 | 0.6 - 0.61 |
| Close: | 0.6 - 0.61 | 0.61 - 0.62 |
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Wed, 07 Oct 2026
Actuate Therapeutics And 2 Other Promising Penny Stocks To Watch - Webull
Tue, 06 Oct 2026
Actuate Therapeutics Registers 50 Million Shares for Public Offering at $0.819 Each - Kalkine Media
Tue, 06 Oct 2026
At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. - Stock Titan
Wed, 02 Sep 2026
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance
Tue, 18 Aug 2026
Actuate Therapeutics stock gets FDA clearance for elraglusib trial - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 56.2 (%) |
| Shares Short | 1,330 (K) |
| Shares Short P.Month | 1,170 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -213.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 15.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|